



February 22, 2013

Dear CardioGen-82® Customer:

The purpose of this letter is to provide you with information regarding recent delays in the shipments of CardioGen-82® (Rubidium Rb 82 Generator) to our customers.

In December and January, we experienced manufacturing delays that set back our production schedule and, as a result, impacted the timely shipment of generators to customers. We have, in turn, focused on an overall process improvement plan, including a more effective and timely "Generator Release Process" as well as a communication plan which includes immediate alerts for shipment information and any potential issue that may impact generator delivery to your facility.

Compounding these manufacturing delays are limitations due to raw material (Sr-82) procurement and supply, such as fluctuations in Sr-82 supply throughout the year due to cyclotron/accelerator operational schedules. We work closely with our suppliers to develop generator delivery schedules that recognize the monthly CardioGen-82 generator needs of our customers. In addition, we have established several options for CardioGen-82 delivery schedules based on the specific needs of the individual customers. Our intent is to provide you with a generator based on the optimal delivery schedule (3, 4, 5 or 6 week delivery). However, occasional modification to the customer's optimal delivery schedule will occur from time to time despite our best efforts. We will continue to work closely with our Sr-82 suppliers to increase and maximize the availability of product throughout the year.

We are pleased to inform you that production schedules have resumed and that you will begin to see a return to normal delivery shortly. We realize such delays can impact your ability to provide Cardiac PET MPI studies as well as managing your staff and, ultimately, your patients. We understand that, despite Bracco exercising its utmost due diligence, these circumstances may impact our customer sites, and we sincerely appreciate the loyalty and support of our customers. We are working diligently to improve all aspects of the process and additionally improve our communication with you.

Please feel free to contact me if you have any questions or would like to address a specific issue.

Regards,

Kim McDaniel
Senior Director, Sales and Market Support
Nuclear Medicine